http://www.fpnotebook.com/
NelfinavirAka: Viracept
- Mechanism
- Efficacy
- Dosing
- Adult: 750mg PO tid
- Pediatrics: 20-30 mg/kg tid
- Take with a meal or light snack
- Adverse Effects
- Well tolerated
Viracept (C0525004) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D019888 |
| English | Agouron Brand of Nelfinavir Mesylate, Roche Brand of Nelfinavir Mesylate, Viracept |
| Sources | CSP, MSH, NCI, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
Nelfinavir (C0525005) | |
|---|---|
| Definition (MSH) | A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. |
| Definition (CSP) | HIV protease inhibitor. |
| Definition (NCI) | A synthetic antiviral agent. Nelfinavir selectively inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. In vivo, this agent exhibits broad tissue distribution compared to related agents. (NCI04) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D019888 |
| English | Nelfinavir, NELFINAVIR PREPARATION, NFV |
| Spanish | nelfinavir |
| Parent Concepts | Antiviral Agents (C0003451), Isoquinolines (C0022248), Protease Inhibitor (C0033607), Retroviral protease inhibitor (C1268897), Drug allergen (C1320237), HIV Protease Inhibitors (C0162714) |
| Sources | CSP, LNC, MSH, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
